Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foes
| Autor: | Simonetta Lugari, Alberto Mondelli, Serena Bursi, Giovanna Onfiani, Amedeo Lonardo, E. Pellegrini, Fabio Nascimbeni, Francesca Carubbi |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Cirrhosis Drug-induced liver injury 030204 cardiovascular system & hematology Chronic liver disease Gastroenterology 03 medical and health sciences Liver disease 0302 clinical medicine Non-alcoholic Fatty Liver Disease Fibrosis NAFLD Internal medicine Nonalcoholic fatty liver disease medicine Animals Humans HCC Precision Medicine business.industry NASH Statins nutritional and metabolic diseases Cardiovascular risk Cardiology and Cardiovascular Medicine medicine.disease digestive system diseases 030104 developmental biology Hepatocellular carcinoma Hydroxymethylglutaryl-CoA Reductase Inhibitors Steatosis Metabolic syndrome business |
| Zdroj: | Atherosclerosis. 284:66-74 |
| ISSN: | 0021-9150 |
| Popis: | Nonalcoholic fatty liver disease (NAFLD) describes a spectrum of alcohol-like hepatic histological changes, which occur in the absence of any competing causes of chronic liver disease, notably including significant alcohol consumption. A close and bi-directional relationship links NAFLD with the metabolic syndrome (MetS), and concurrent MetS will hasten the progression to more severe forms of NAFLD, including cirrhosis and hepatocellular carcinoma (HCC). Patients with NAFLD will typically exhibit atherogenic dyslipidemia and increased cardiovascular risk (CVR). Statins are among the most widely prescribed lipid-lowering drugs. Their use has historically been hampered, in individuals with liver disease, owing to the fear of hepatotoxicity. However, studies suggest that statins are not only effective in reducing cardiovascular events, but may also exert multiple beneficial effects on the liver. CVR in those with NAFLD has extensively been covered by our group and others. This updated clinical narrative review will critically examine the effects of statins on the pathogenesis of NAFLD, including the key elementary pathological lesions of NAFLD, i.e. steatosis, inflammation and fibrosis, and its liver-related complications, i.e. cirrhosis, portal hypertension and HCC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect